



200.0 126 Gp 186

part-Fin

**IN THE UNITED STATES PATENT OFFICE**

Application Serial No. 07/838,675

Our Ref.: PT-1039

Applicants: Rudolf Edgar Falk, and  
Samuel Simon Asculai

Agent: Ivor M. Hughes  
Suite 200  
175 Commerce  
Valley Dr., West,  
Thornhill, Ontario  
L3T 7P6

Title : TREATMENT OF DISEASE EMPLOYING  
HYALURONIC ACID AND NSAIDS

Inventors : Rudolf Edgar Falk, and  
Samuel Simon Asculai

Filed : February 21, 1992

Examiner : Mr. Stephen J. Martin, PhD

Group Art Unit: 1806

Due Date: January 14, 1995  
(January 17, 1995)

January 13, 1995

The Commissioner of Patents,  
UNITED STATES PATENT OFFICE,  
2011 Jefferson Davis Highway,  
Crystal Plaza, Room 1303  
Arlington, Virginia  
22202 U.S.A.

Dear Sir:

**SUPPLEMENTARY INFORMATION  
DISCLOSURE STATEMENT**

Applicants and the undersigned are aware of "patents, publications, or other information" which they believe may be material to the examination of the above-identified application. Copies of these items were previously submitted to the Examiner with Application Serial No. 07/675,908 with the respective Response filed January 6,

RECEIVED  
MAR 06 1995  
GROUP 1500  
GROUP 1800

1995 and are therefore not included with this Supplementary Information Disclosure Statement. In addition, one sheet of Form PTO-1449 listing them, are submitted herewith pursuant to 37 C.F.R. §§ 1.97-1.99 and to the duty of disclosure set forth in 37 C.F.R. § 1.56.

Although this Information Disclosure Statement identifies references which may be "material," it is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" (within the meaning of 35 U.S.C. § 102 103) as to the invention disclosed and claimed in this application unless specifically designated as such. Moreover, no representation is intended as to the relative relevance of any portion of the references or as to the relevance among references, whether cited in this Statement or elsewhere.

In accordance with 37 C.F.R. § 1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a novelty search has been made or that no other information which may be material (as defined in 37.C.F.R. § 1.56(a)) exists.

### **UNITED STATES PATENTS**

USP 2,583,096  
USP 3,436,454  
USP 3,887,703  
USP 4,272,522  
USP 4,716,224  
USP 4,853,226  
USP 4,946,870

### **AUSTRALIAN PATENTS**

AU-B-72117/87  
AU 30806/84

### **EUROPEAN PATENTS**

EP 0,378,852

**GREAT BRITAIN**

GB 1,283,892  
GB 2,099,826-A

**JAPANESE PATENTS**

JP-A-116678/88  
JP 61-233,622  
JP 57-183,707

**GERMAN PATENTS**

DE 2,364,373

---

## OTHER DOCUMENTS

Alaverdyan MI, Ter-Avetisyan AT.

**Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemia.**

*Bulletin of Experimental Biology and Medicine* 1967; 64(9): 967-969.

Balazs EA, Gibbs DA.

**The rheological properties and biological function of hyaluronic acid.**

In: *Chemistry and Molecular Biology of the Intercellular Matrix. Volumes III.* New York: Academic Press, 1970. PP. 1241-1253.

Balazs EA, Band P.

**Hyaluronic acid: Its structure and use.**

*Cosmetics & Toiletries* . Polymers in Cosmetics 1984; 99: 65-72.

Camber O, Lundgren P.

**Diffusion of some low molecular weight compounds in sodium hyaluronate.**

*Acta Pharmaceutica Suecica* 1985; 22(6): 315-320.

Camber O, Edman P, Gurny R.

**Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits.**

*Current Eye Research* 1987; 6(6): 779-784.

Chang S-C.

**Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit.**

*Dissertation Abstracts International* 1988; 49(2): 367-B.

Cravioto, R.O., et al.

**Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoïd From Vitreous Humor in Depressing Blood-Sugar Levels**

*Science* (1950); Vol. 111: 520-521

Gieldanowski, Jerzy; Skowronska, Jadwiga

**Studies on immunosuppressive and anti-inflammatory effect of adriamycin.**

*Arch. Immunol. Ther. Exp.* (1980); 28 (3): 439-446

Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B.  
**Effects of adjuvants to local anaesthetics on their duration.**  
*Acta Anaesthesiol. Scand.* 1985; 29: 384-388.

Hurd ER  
**Immunosuppressive and anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate.**  
*Arthritis and Rheumatism* (1973 Jan-Feb); 16 (1): 84-88

Idson B.  
**Polymers in skin cosmetics.**  
*Cosmetics & Toiletries* 1988; 103: 63-68.

Johansson A, Hassan H, Renck H.  
**Effects of adjuvants to local anaesthetics on their duration.**  
*Acta Anaesthesiol. Scand.* 1985; 29: 736-738.

Kalbhen D.A.  
**The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthritis and its counteraction by a biological GAG-peptide complex (Rumalon®).**  
*Z. Rheumatol* (1982); 41: 202-211

Katsu M., Abe T., Shimada S.  
**Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence.**  
*Nippon Rinsho* (1968 Jan); 26(1): 89-95

Kreis H, Chkoff N, Droz D, et al.  
**Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients.**  
*Transplantation* (1984 Feb.); 37(2): 139-145

McIlwraith W.  
**Current concepts in equine degenerative joint disease.**  
*Journal of the American Veterinary Medical Association* 1982; February 1: 239-250.

Mizushima Y.  
**Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future.**

*Nippon Rinsho* (Jan. 1986); 26(1): 61-65

Nizolek DJH, White KK.

**Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A review.**

*The Cornell Veterinarian* 1981; 71(4): 355-375.

Pigman W, et al.

**Acide hyaluronique et facteurs de perméabilité tissulaire.**

*Bull. Soc. Chim. Biol.* 1963; 45(2-3): 185-202.

Pruett RC, Schepens CL, Constable IJ, Swann DA.

**Hyaluronic acid vitreous substitute.**

In: *Vitreous Surgery and Advances in Fundus Diagnosis and Treatment*. Freeman H.M., et al., Editors. Appleton-Century-Crofts, 1977: Chapter 55, pp. 433-444.

Reim M, Teping C.

**Surgical procedures in the treatment of most severe eye burns.**

*Acta Ophthalmologica* 1989-Supplementum 192; 67: 47-54.

Rydell NW, Balazs EA.

**Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation.**

*Clinical Orthopaedics and Related Research* (1971); 80(October): 25-29.

Saba P, Galeone F, Salvadorini F, Guarguaglini M, Ombrato M.

**Investigation of the antihyperlipemic activity of an association of clofibrate and extractive mucopolysaccharide complex.**

*Current Therapeutic Research* (1978); 23(4): 455-463.

Stegman R, Miller D.

**Use of sodium hyaluronate in severe penetrating ocular trauma.**

*Acta Ophthalmol.* (1986); 18: 9-13.

Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, Rizzitelli E, Baratti C, et al.

**Prevention of wound dehiscence in severely obese patients with jejunio-ileal by-pass: The role of hyaluronic acid.**

*Pharmatherapeutica* (1988); 5(4): 233-239.

Sertoli P, Merello A, Parodi M.

**L'acido ialuronico, per uso topico, nella cura delle ulcere trofo-circolatorie degli arti inferiori. (Comunicazioni).**

*Giornale Italiano di Dermatologia* (1970); 45(8): 468-471.

Walther, M.

**The Prevention of Striae Cutis Distansae During Pregnancy.**

*Mineva Gynecologia* (1981); Vol. 33: 497-499

Weirich E.G., Longauer J.K., Kirkwood A.H.


**Dermatopharmacology of salicylic acid. III. Topical contra-inflammatory effect of**

**salicylic acid and other drugs in animal experiments.**

*Dermatologica* (1976); 152 (2): 87-99

---

Respectfully submitted,



Ivor M. Hughes,  
Registration No. 27,759  
Agent for Applicants